Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/102152
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLai, R.en
dc.contributor.authorKatalinic, N.en
dc.contributor.authorGlue, P.en
dc.contributor.authorSomogyi, A.en
dc.contributor.authorMitchell, P.en
dc.contributor.authorLeyden, J.en
dc.contributor.authorHarper, S.en
dc.contributor.authorLoo, C.en
dc.date.issued2014en
dc.identifier.citationWorld Journal of Biological Psychiatry, 2014; 15(7):579-584en
dc.identifier.issn1562-2975en
dc.identifier.issn1814-1412en
dc.identifier.urihttp://hdl.handle.net/2440/102152-
dc.description.abstractOBJECTIVES: Research studies have reported impressive antidepressant effects with ketamine but significant knowledge gaps remain over the best method of administering ketamine, and the relationships between dose, antidepressant response and adverse effects. METHODS: In this pilot dose-finding study, the efficacy and tolerability of ketamine given by rapid intravenous (i.v.) infusion were assessed in a double-blind, placebo-controlled, crossover design, in four subjects with treatment- resistant depression. Each subject received up to four i.v. doses of ketamine (0.1, 0.2, 0.3, 0.4 mg/kg), given over 2-5 min, 1 week apart, and one randomly inserted placebo treatment. RESULTS: Three of four subjects achieved antidepressant response (≥ 50% decrease in Montgomery-Asberg Depression Rating Scale scores), two at the minimum 0.1 mg/kg dose, though all relapsed within a week. For two subjects, the greatest improvement occurred at the highest dose received. Rapid infusion over 2 min led to significant adverse psychotomimetic effects which also increased proportionately with ketamine dosage. CONCLUSIONS: This is the first trial to present dose-response data of ketamine efficacy and psychomimetic effects in depressed subjects. Antidepressant efficacy may be dose-related. Psychotomimetic effects were dose-related. Rapid infusion over 2 min may not be a feasible clinical approach to treatment, given poor tolerability.en
dc.description.statementofresponsibilityRosalyn Lai, Natalie Katalinic, Paul Glue, Andrew A. Somogyi, Philip B. Mitchell, John Leyden, Simon Harper, and Colleen K. Looen
dc.language.isoenen
dc.publisherTaylor and Francisen
dc.rights© 2014 Informa Healthcareen
dc.subjectKetamine; depression; dose-response relationship; drug-related side effects and adverse reactions; intravenous administrationen
dc.titlePilot dose-response trial of I.V. ketamine in treatment-resistant depressionen
dc.typeJournal articleen
dc.identifier.rmid0030010501en
dc.identifier.doi10.3109/15622975.2014.922697en
dc.identifier.pubid116395-
pubs.library.collectionMedicine publicationsen
pubs.library.teamDS14en
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidSomogyi, A. [0000-0003-4779-0380]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.